Cytosorbents (CTSO) Free Cash Flow (QoQ) (2010 - 2026)
Cytosorbents (CTSO) Free Cash Flow (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.10 Bn | 176.81 Bn | 6.27 Bn |
| 2 | Stryker | 128.79 Bn | 125.91 Bn | 3.81 Bn |
| 3 | Medtronic | 108.97 Bn | 99.75 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.57 Bn | 67.12 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.40 Bn | 26.11 Bn | 1.98 Bn |
| 7 | Dexcom | 28.32 Bn | 27.20 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.94 Bn | 26.36 Bn | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn |
| 10 | Cytosorbents | 23.84 Mn | 19.04 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76.22% |
| Dec 31, 2025 | -90.17% |
| Sep 30, 2025 | -67.79% |
| Jun 30, 2025 | 55.42% |
| Mar 31, 2025 | -62.51% |
| Dec 31, 2024 | 18.39% |
| Sep 30, 2024 | 45.66% |
| Jun 30, 2024 | 1.29% |
| Mar 31, 2024 | 29.81% |
| Dec 31, 2023 | -33.41% |
| Sep 30, 2023 | 24.91% |
| Jun 30, 2023 | -123.06% |
| Mar 31, 2023 | -1,890.07% |
| Dec 31, 2022 | 101.40% |
| Sep 30, 2022 | -63.75% |
| Jun 30, 2022 | 14.38% |
| Mar 31, 2022 | 3.32% |
| Dec 31, 2021 | -213.17% |
| Sep 30, 2021 | -3.24% |
| Jun 30, 2021 | -1.87% |